Research & Development
Efforts for Research & Development
Our goal is to develop therapeutics for patients with "overlooked medical needs" as quickly as possible. To achieve this goal, we promote open innovation-based drug discovery of small molecule and nucleic acid drugs, regardless of therapeutic area.
Research & Development Structure
Our company has drug discovery capabilities ranging from initial planning and investigation to applications for approval, and we are evolving our drug discovery capabilities by adding the modality of nucleic acid medicines to our drug discovery foundation of small molecule drugs. Furthermore, in order to quickly resolve issues in the drug discovery process, we aim to create both an open atmosphere where opinions can be exchanged vigorously and a system that strongly supports skill development.
Our research and clinical development groups, which combine a wide range of highly specialized expertise, transcend organizational boundaries and focus on "collaboration," "mobility," and "enthusiasm," as they continue to take on the challenge of delivering therapeutic drugs as soon as possible.
Functions
| Planning and Investigation |
- By proactively communicating with medical professionals, we are committed to identifying true medical needs and are challenging ourselves to create the seeds of "therapeutic drugs that meet overlooked medical needs."
|
| Research |
[Exploratory and Optimization Studies]
- We aim to obtain high-quality lead compounds by prioritizing concepts that meet medical needs, closely sharing information in the Design-Make-Test-Analyze cycle, and focusing on the quality of the the science and the candidate compounds. Furthermore, we are leveraging AI in drug discovery to improve success rates and enhance research efficiency.
[Preclinical Studies]
- We actively conduct translational research to confirm efficacy and safety, aiming to increase the chances of successful proof of concept in clinical development.
[CMC Research]
- We are committed to patient-centered drug development that takes patient convenience into consideration, and conduct research aimed at process design for APIs and formulations that ensure high quality.
- We are also actively involved in drug fostering and evolution, and our "OSDrC Technology" was born from this commitment.
|
| Clinical Development |
- We utilize our know-how in creating efficient development packages and clinical trial plans for a wide range of diseases to take on challenges and advance clinical development even in therapeutic area where we have no experience.
- Using a patient-centered approach, we aim to deliver new treatments as soon as possible. We build relationships based on trust with medical institution staff and conduct ethical and high-quality clinical trials.
|
Mie Research Park
Located in a lush green area, Mie Research Park is our research center for drug discovery and includes the Pharmaceutical Research Laboratories and the CMC Research Laboratories. It mainly handles the functions of "Discovery and Optimization Research," "Preclinical studies," and "CMC Research," and seamlessly responds to all research topics. Furthermore, with a focus on grasping true medical needs, we are also challenging ourselves with planning and research to create the seeds for new therapeutics.
Open Innovation Initiatives
We have shifted from an in-house drug discovery model to one based on open innovation. We are actively collaborating with domestic and international research institutions (academia, venture companies, domestic and international pharmaceutical manufacturers, etc.) that have drug discovery seeds and technologies, aiming to create therapeutic drugs that meet "overlooked medical needs."
※This is a one-stop service that provides all of the roles necessary to enter the Japanese market, from development, application for approval of manufacturing and marketing, manufacturing, sales and marketing, and distribution, through the cooperation of the three group companies, Suzuken Group, EPS Group, and Bushu Pharma.
WISH LIST(Joint research and drug discovery partnerships with academia and drug discovery ventures)
We are looking for collaborative research and drug discovery partnerships with academia and companies.
| Modality |
Small Molecule Drugs |
Nucleic Acid Therapeutics
（Antisense oligonucleotide，siRNA） |
|
Therapeutic Domain
|
"Overlooked medical needs"
regardless of therapeutic area
|
|
【Preferred therapeutic areas】
- Neuromuscular diseases
- Endocrine diseases
- Rare diseases
|
【Preferred therapeutic areas】
- Single gene disorders
(including diseases unique to Japan)
|
|
Target Stage
|
Pharmaceutical research (target identification) ～Non-clinical research |
| Research Results ※※ |
Confirm a positive effect on pathological conditions
(using animal models or patient cells, etc.) |
- Identify pathogenic gene
- Clarify involvement in pathogenesis
|
※※This includes new drug discovery technologies for targets that are difficult or cannot be targeted with conventional technologies
Contact Us
Please contact us if you are interested in joint research and drug discovery partnerships.
